Total
0
Shares
Race Oncology (ASX:RAC) - Chief Medical Officer, David Fuller
Chief Medical Officer, David Fuller
Source: Race Oncology
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The first patient in Race Oncology’s (RAC) Phase 1b/2 acute myeloid leukaemia (AML) trial in Israel has been dosed with a novel treatment
  • The trial is assessing the efficacy of RAC’s drug Zantrene in combination with two other drugs in patients with relapsed or refractory AML
  • Race Oncology is also conducting a separate Phase 2 trial of Zantrene in patients with intramedullary AML in Australia
  • Shares are trading flat at $3.39 at 11:44 am AEST

The first patient in Race Oncology’s (RAC) Phase 1b/2 acute myeloid leukaemia (AML) trial in Israel has been dosed with a novel treatment.

The trial at the Chaim Sheba Medical Center is being led by Professor Arnon Nagler who conducted the Phase 2 single agent Zantrene trial in relapsed and refectory AML patients.

The study is assessing the efficacy of Race Oncology’s cancer drug Zantrene (bisantrene dihydrochloride) in combination with fludarabine and clofarabine to treat patients with relapsed or refractory AML.

Race Chief Medical Officer David Fuller said the company was delighted to see the clinical project under way.

“This study is also an important step in our journey towards approval of Zantrene in this area of high unmet medical need,” he said.

Phase 1b will be a dose-escalation stage and will assess for any dose-limiting toxicities. Phase 2 will enrol up to 17 patients and evaluate the efficacy of the novel combination treatment at the dose determined in the previous stage.

The trial is expected to take between 36 and 40 months to complete. Over this time Race Oncology will pay Chaim Sheba a total fee of US$668,739 (A$910,500) at various milestones.

Race Oncology is also conducting a separate Phase 2 trial of Zantrene in patients with intramedullary AML in Australia.

Shares were trading flat at $3.39 at 11:44 am AEST.

RAC by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug